INTRODUCTION
Chemotherapy is a significant modality of cancer management used alone or in combination with other therapies to treat various tumours (Gottesman et al., 2001; Holohan et al., 2013) . Tumour cell resistance is a major cause of chemotherapy failure, and therefore it constitutes a major problem in cancer therapy (Rivera and Gomez, 2010; Holohan et al., 2013) . Tumour chemoresistance can be intrinsic or acquired (adaptive). Intrinsic resistance manifests as a low sensitivity of tumour cells to the chemotherapeutic compound due to pre-existing resistance mechanisms, whereas acquired resistance develops in chemo-sensitive tumour cells during treatment (Holohan et al., 2013) . Cancer recurrence after chemotherapy may be a result of the regeneration of the cancer cell population by a few cancer cells that have become less sensitive to the cytotoxic compound during therapy (Dean et al., 2005) . Another hypothesis for cancer resistance is based on tumour heterogeneity, i.e. chemotherapy may exert a selection pressure on naturally resistant cells that eventually are capable of restoring the cancer cell population (Holohan et al., 2013) . This mechanism may involve cancer stem cells (CSCs) that possess an intrinsic potential to escape the effects of chemotherapy. The transfer of chemoresistance properties from CSCs or similar cells to daughter cells has been observed in several studies (Dean et al., 2005; Moitra et al., 2011) . The survival of some cells under selective pressure of one chemotherapy compound may result in chemoresistance to other structurally distinct chemotherapeutic agents with different modes of action (i.e., multidrug resistance). Multi-drug resistant cells have been associated with increased tumour aggressiveness, recurrence, and metastasis (Saxena et al., 2011) , therefore studies of chemoresistance mechanisms may allow for the development of effective treatment efficiency biomarkers and new therapeutic approaches to cancer therapy (Tegze et al., 2012) .
Doxorubicin is an anthracycline cytotoxic compound that has been used in chemotherapy for decades (Cortós-Funes and Coronado, 2007; Xiang et al., 2017) . Doxorubicin intercalates between bases in DNS, inhibiting human DNA topoisomerase 2-a and inducing the formation of potentially cytotoxic reactive oxygen species (Gewirtz, 1999) . It enters the cell via a passive diffusion mechanism, and the resulting intracellular concentration exceeds the extracellular concentration by 50-100 fold (Cortós-Funes and Coronado, 2007) . Depending on dosage levels doxorubicin-induced DNA damage leads to the arrest of the cell cycle in G1 and G2 phases, apoptosis (Gewirtz, 1999) or senescence (Smith et al., 2006) . Treatment failure due to acquired resistance has been observed also in doxorubicin treated patients (Smith et al., 2006) . The main mechanisms mediating tumour cell resistance to doxorubicin are: (i) increased expression of drug transporter proteins, (ii) modifications in target molecule(s), and (iii) altered cell death signalling (Cox and Weinman, 2016) .
According to the clonal evolution theory, a tumour consists of genetically and phenotypically different cell populations (Nowell, 1976) . Tumour heterogeneity provides cellular diversity for resistance, self-renewal capability and growth adjustments (Liang et al., 2010) .
Tissue stem cells possess properties of self-renewal and virtually unlimited proliferation potential, maintain the pool of undifferentiated tissue cells, and their differentiation potential may be induced by certain stimuli (Rajaraman et al., 2006) . CSCs possess similar properties (Achuthan et al., 2011) . Although cancer stem cell theory is a controversial concept of cancer biology, experimental evidence for the existence of stem cells or stem-like cells in tumours is extensive. Recently, the expansion of CSCs subpopulations in cell culture has been associated with the stress-induced (hypoxia, chemotherapy, radiotherapy) development of polyploid, multinucleated giant cells that are capable of replenishing the tumour cell population (Mirzayans et al., 2018) . CSCs have been characterised by a particular pattern in the expression of several marker genes, e.g., ALDH1A, CD24, CD44, CD133, and so called "stemness" genes of normal stem cells, e.g., SOX2, OCT3/4, NANOG (Liu et al., 2013; Zhang et al., 2013) , as well as markers related to epithelialmesenchymal transition, like ITGB1, ITGB3, and ITGA6 (Brooks et al., 2016) .
Experimental studies and clinical trials have shown intrinsic resistance of CSCs to chemo-and radiotherapy. Positive selection for CSCs during therapy leads to recurrence of more aggressive and more resistant tumours with increased metastatic potential (Vinogradov and Wei, 2012) .
In this study, we assess the dynamics of stem-like properties in the breast cancer cell line MDA-MB-231 after single pulsed treatment with doxorubicin.
The aim of the study was to evaluate the alterations of stem-like properties in a triple-negative breast cancer cell line MDA-MB-231 during and after pulsed treatment with the cytotoxic agent doxorubicin (DOX) in comparison to untreated controls.
MATERIALS AND METHODS
Cell culture maintenance. The triple negative breast cancer cell line MDA-MB-231 (ATCC HTB®-26) was cultured in a DMEM/F12 (1:1) (Thermo Fisher Scientific) medium with 10% foetal bovine serum (FBS) (Sigma Aldrich); 1 x penicillin/streptomycin (Sigma Aldrich) in a humidified atmosphere containing 5% CO 2 at 37 o C. TripLE (ThermoFisher Scientific) was used for cell subculturing. During passaging cell counts and cellular viability were determined in a haemocytometer chamber (Improved Neubauer) with exclusion dye Trypan Blue (Sigma Aldrich).
Pulsed treatment with doxorubicin. After treatment group cultures (duplicate) had reached 50-60% confluence. They were pulse-treated with 0.26 µM doxorubicin (DOX) (Ebewe Pharma) for 48 h (treated or DOX cultures). Then the drug containing the medium was removed, and the cultures were rinsed with Dulbecco's PBS (D-PBS) (Sigma Aldrich) and further cultured in a fresh drug-free medium for another 24 h prior to passaging to post-treatment (DOX+1) cultures. Untreated cultures were grown in parallel as a control (two sequential cultures: Control and Control+1). For control, Control+1 and DOX cultures cells were seeded at a density of 3.5 × 10 3 /cm 2 in 75 cm 2 flasks (Sarstedt); reseeding after pulsed treatment with doxorubicin (post-treatment cultures) was performed at a density of 6.0 × 10 3 /cm 2 in 75 cm 2 flasks.
Sulforhodamine B (SRB) assay. Whole-well surrogate assay sulforhodamine B (SRB) assay was performed according to Skehan et al., 1990 and Vichai et al., 2006. In brief, at pre-specified time-points cells on 96-well plates were fixed with 10% (wt/vol) tricloroacetic acid (Sigma Aldrich) (final concentration), rinsed four times under slowly running tap water and air-dried. Then plates were incubated with a 4 mg/ml SRB (Sigma Aldrich) solution in 1% acetic acid (vol/vol) (Sigma Aldrich) for 30 min and quickly rinsed six times with 1% acetic acid. Plates were air-dried and 10 mM Tris base solution (pH 10.5) (AppliChem) was added. Plates were shaken on an orbital shaker for 10 min and the solution was transferred to a fresh plate. Absorbance (A) was measured at 565 nm in a microplate reader (Infinite M200 PRO, Tecan To estimate inhibitory concentration 50% (IC 50 ) and growth rate 50% (GR 50 ) the dose-response curves obtained in cytotoxicity assay results were analysed with the use of statistical software R package GRmetrics (Hafner et al., 2016 , https://www.R-project.org). The value of GR 50 is normalised and does not depend on the division rates of cultures during the cytotoxicity assay (Hafner et al., 2016) .
Long-term colony formation assay. During passaging cells were seeded on 24-well plates (1 ml/well) (Cell+, Sarstedt) in triplicates at a density of 20 cells per well. After 11 days, the cell colonies on the plate were fixed using 10% TCA, stained with 0.01% (wt/vol) crystal violet (Serva) and the colonies (³ 50 cells) were counted manually. Data were analysed using statistical software R and RStudio (Anonymous, 2018; https://cran.r-project.org). Colony forming ability (%) was estimated by the equation:
where Y -colony forming ability (%), K -number of colonies/well, 20 -number of seeded cells/well. The average values and standard deviations for each culture were calculated. The statistical significance for colony-forming unit counts in different cultures was determined by the Student's t-test.
qPCR and gene expression analysis. Isolation of RNA from 1 × 10 6 cells was performed using TRIzol reagent (Thermo Fisher Scientific) according to the manufacturer's protocol. Total concentration of RNA was determined by a NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific). The quality of RNA was determined on 2% agarose gel electrophoresis. After RNA treatment with DNaseI (Sigma Aldrich) and purification using NucleoSpin XS (Macherey Nagel), 2 µg of RNA was used for cDNA synthesis with a High-Capacity cDNA Reverse Transcription kit (Thermo Fisher Scientific). The quality of synthesised cDNA was assessed using a FIREPol DNA polymerase PCR kit (Solis BioDyne) with housekeeping genes ACTB1 and 18SRNA.
We used a 5 ng/reaction of cDNA in triplicate for qPCR (real-time PCR) with 5x HOT FIREPol EvaGreen qPCR Plus (ROX) kit (Solis BioDyne). The qPCR was performed for 40 cycles with the following conditions: 95 C for 15 s, 58 C for 30 s and 72 C for 30 s on a real-time PCR cycler Viia7 (Thermo Fisher Scientific). The oligonucleotide sequences are shown in Table 2 .
Quality control was performed for each gene in technical triplicate followed by analysis of data. Quality control included the analysis of product melting and amplification curves. If there was more than one peak in the melting curve, the product was tested using agarose gel electrophoresis. Data from samples containing more than one correct product and from samples that did not reach the threshold of amplification were excluded from further analysis. Criteria for data quality were: Ct values that were located more than three SDs from the average value of the triplicate were not included in the analysis. As a threshold values for expression, the gene was assumed to be expressed if the average Ct value was below 35. The transcription level of the gene in each culture was normalised against endogenous control genes (ACTB, 18S rRNA), thus obtaining dCt values. Changes in gene expression were expressed relative to the control cultures (without DOX treatment) using the ddCt value and calculating the number of relative changes (RQ) (Livak and Schmittgen, 2001) . If Ct was undetermined, a value of 41 was used. A heat map was generated using the statistical software R programme 3.5.1. package gplots (Anonymous, 2018 ; https://cran.r-project.org). The statistical significance of the expression changes was determined by a two-tailed unpaired t-test using six values in each group.
RESULTS
Changes in cell morphology and proliferation rate after pulsed treatment with doxorubicin. After pulsed treatment of breast cancer cell line MDA-MB-231 culture with 0.26 µM doxorubicin for 48 h the proportion of the giant cells in DOX cultures increased in comparison to controls (Fig. 1) . Treatment with DOX resulted in lower cell counts and viability at the passaging in the DOX cultures vs. control cultures (viability in DOX treated cultures and controls of 86.6% and 90-95%, respectively).
The growth of the post-treatment (DOX+1) cultures displayed two distinct phases: during the recovery period, the culture contained an increased proportion of large cells and dying cells, while further growth was characterised by colony forming and regeneration of the cellular population (Fig. 2) .
During the first two growth weeks, the DOX+1 cultures displayed mostly dying (confluence dropped from 40% to 5-10%) cells. On day 10 after passaging to DOX+1 culture, the formation of new colonies containing morphologically distinct, smaller cells was observed (Fig. 3, d10 , green arrow), and further growth was characterised by increased forming of colonies and regeneration of the cellular population (Fig. 3) .
Also, the morphology of the cells in the treated culture differed from the control cultures, and displayed heterogeneity, including mesenchymal, epithelial, giant and neuronal-type cells (Fig. 4) .
To assess changes of growth parameters in post-treatment cultures, growth curves were generated and population doubling times (PDTs) were estimated (Fig. 5) . The PDT in control cultures were significantly less (p < 0.001) than in post-treatment cultures (27.73 ± 0.36 h and 37.46 ± 0.17 h, respectively), i.e. the cellular population that survived doxorubicin treatment displayed delayed and/or slower growth.
Sensitivity of MDA-MB-231 to cytotoxic substances after doxorubicin treatment. To assess the impact of pulsed doxorubicin treatment on the sensitivity of MDA-MB-231 cells to doxorubicin, cisplatin, vinblastine and 5-fluorouracil, a cytotoxicity test was performed in control and DOX+1 cultures (Fig. 6 ). Based on both GR50 and IC50 values, control and post-treatment cultures were more sensitive to vinblastine and doxorubicin (values in nanomolar range) than to cisplatin and 5-fluorouracil (values in micromolar range) (Table 3 ). Pulsed treatment with DOX resulted in increased resistance to doxorubicin in the DOX+1 cultures (GR 50 of 285.6 and 543.1 nM in control and DOX+1 cultures, respectively; fold change of 1.9). This increase in resistance to doxorubicin was accompanied by increased sensitivity to cisplatin, vinblastine and 5-fluorouracil (sensitivity fold change values of 0.85, 0.53 and 0.69, respectively).
Interestingly, adjustment of sensitivity metrics for growth rate (GR 50 ) (Hafner et al., 2016) as compared to the traditional cytotoxicity estimation (IC 50 ) revealed increased sensitivity to the tested substances (by factor of 1.50 to 3.50) and also showed that the sensitivity of post-treatment cultures to cisplatin, vinblastine and 5-fluorouracil actually decreased (Table 3, Changes of the stem-like properties in MDA-MB-231 cell cultures after doxorubicin treatment and in posttreatment culture. Two methods were used to determine the effects of pulsed treatment with doxorubicin on stemlike properties in the studied breast cancer cell line MDA-MB-231: changes in the transcriptomic expression of stemness-associated genes and long-term colony formation assay. Pulsed treatment with doxorubicin led to significant 
Fig. 5. Growth curves of control (red) and post--treatment (DOX+1) (blue)
MDA-MB-231 cultures as determined by SRB assay. To obtain growth curves, cells were plated on 96-well plates at a density of 5 × 10 3 cells per well. Cells were fixed for SRB assay at 24 h intervals starting 24 h after initial plating (12 technical replicates for each time-point). A surrogate of total cell numbers at each time-point was determined as absorbance value in SRB assay. The error bars show standard deviations. increase in the transcriptional expression of ALDH1A, CD24, CD44 genes and decrease in ITGA6, ITGB1 and POU5F1 genes during the acute post-treatment phase (DOX treated cultures) (Fig. 7) . Recovery phase (DOX+1 cultures) was characterised by decrease (partial normalization) of the transcriptomic expression levels for all tested genes. A statistically significant decrease in the transcriptomic expression of CD24, ITGA6 and ITGB1 genes was observed also in the second passage (Control+1 cultures) as compared to the first passage (control cultures) cells.
Pulsed doxorubicin treatment resulted also in statistically significant increase of colony formation ability in DOX+1 cultures by 58.4% as compared to control cultures (colony formation ability of 48.8 ± 12.0% and 30.8 ± 9.5%, respectively) (Fig. 8) .
DISSCUSION

Pulsed treatment of MDA-MB-231 with doxorubicin.
Models of cell culture are the standard approach for in vitro chemotherapy resistance studies. Cell culture allows to determine the cellular response to the effects of chemotherapeutic compounds, and to develop cells with acquired resistance by single or multiple exposure to the drugs (McDermott et al., 2014) . To select for clinically relevant subpopulations and to develop multi-resistant cell lines, cells cultures are exposed to relatively low concentrations of cytotoxic compounds in a pulsed or continuous manner, thus simulating chemotherapy cycles (McDermott et al., 2014) . For this study, a few pilot experiments (data not T a b l e 3 The cytotoxicity assay was performed at the passaging of the respective culture shown) were conducted to determine the doxorubicin IC 50 for untreated MDA-MB-231 cells. The identified inhibitory concentration (0.26 µM) was used for the pulsed treatment of MDA-MB-231 cells.
GR50 AND IC50 CONCENTRATION VALUES (± STANDARD DEVIATION) FOR TESTED SUBSTANCES IN CONTROL CULTURES (UN-TREATED CELLS) AND POST-TREATMENT CULTURES
Changes in cellular morphology and proliferation rate after pulsed treatment with doxorubicin. One of the primary observations in cultures treated with doxorubicin was not only the increased numbers of suspension cells, but also increased numbers of the giant cells. These observations are in line with the reports showing spontaneous formation of polyploid giant cells in increasing numbers after treatment of cancer cell lines with cytotoxic compounds (Mirzayans et al., 2018) . Cytotoxic compounds induce cell death; however, adaptive response can be initiated in some cells allowing them to survive (Holohan et al., 2013) . In our experiment formation of giant cells with one enlarged nucleus or with multiple nuclei after doxorubicin treatment in MDA-MB-231 cultures was observed. Other studies have shown that giant cells possess properties of CSCs -slow proliferation or lack of proliferation, growth arrest due to stress, and the ability to re-enter the cell cycle afterwards (Weihua et al., 2011) . It has been shown that the giant cells that divide amitotically can promote stemness, giving the rise to new cells with stem-like features via various mechanisms -nuclear budding or bursting, depolyploidisation, horizontal transfer of a "sub-genome" between cells. The division of giant cells, termed neosis (Sundaram et al., 2004) , has been observed in several mammalian cancer, including breast cancer, cell lines (Fei et al., 2015) . Thus, in response to chemotherapy-induced stress, giant cells may initiate genomic re-organisation and give rise to new tumourinitiating cells, contributing to the relapse of the disease (Niu et al., 2016) . Giant cells have demonstrated aggressiveness, increased resistance to cytotoxic compounds (including doxorubicin), capacity for colony-formation and metastases (Weihua et al., 2011; Mirzayans et al., 2018) .
The growth dynamics of doxorubicin-treated MDA-MB-231 cultures in our study is similar to the findings of other in vitro studies. For example, a study with a TP53-mutated cervical cancer cell line exposed to radiation showed increase in numbers of the giant polyploid cells. However, only approximately 2% of those cells were capable avoiding cell death and restoring the cellular population (Erenpreisa et al., 2008) . Similarly, we observed increased numbers of the giant cells along with increased proportion of dying cells in our cultures along with the formation and clustering of small cells on top of the giant cells.
Re-growth of the population of the MDA-MB-231 cells after treatment with doxorubicin was due to formation of cellular colonies. In the post-treatment cultures (DOX+1), colonies and cells with mesenchymal-like morphology were observed. Recovery of the MDA-MB-231 cultures after treatment with doxorubicin was slow as evidenced by larger PDTs of post-treatment (DOX+1) cultures, and colony formation in the post-treatment cultures was observed from day 10 after treatment; on day 16 in the post-treatment (DOX+1) culture the count of cellular colonies was 55 (corresponding to 0.011 % of the seeded cells). This can be explained by increased numbers of giant polyploid cells. Several studies have shown the ability of the giant cells to stimulate epithelial-mesenchymal transition with possible influence on the development of metastasis and resistance to chemotherapeutic compounds (Mirzayans et al., 2018) . (Mirzayans et al., 2018) .
Alterations of MDA-MB-231 sensitivity to cytotoxic compounds after doxorubicin treatment. Cell-growth assays (such as viability and clonogenicity tests) are used to detect cellular sensitivity to chemotherapeutic compounds (McDermott et al., 2014; Mckenna et al., 2017) . Multiresistance can be induced by various mechanisms (Dean et al., 2001) , therefore the sensitivity of cells is tested against several chemotherapy compounds. The sensitivity of posttreatment cultures to several compounds was measured and compared to the control cultures. In addition to doxorubicin, we used several additional cytotoxic compounds: vinblastine (VB) that inhibits cell division through microtubule inhibition (Gottesman et al., 2002) ; cisplatin (CIS) that causes DNA crosslinking inhibiting DNA reparation (Dasari and Tchounwou, 2014) ; and 5-fluorouracil (FU) that is a nucleotide analogue inhibiting tymidylate synthase and therefore DNA and RNA synthesis (Hu et al., 2018) . All these compounds are substrates for multi-resistance associated transporters of the ABC family (Gottesman et al., 2002) .
The growth rate metrics (GR 50 ) used in this study estimate the concentration of the compound that inhibits cellular growth rate by 50 % after adjustment for growth rate, i.e., the number of cell divisions and the seeding density has no effect on this parameter (Hafner et al., 2016; . Based on GR 50 values, our doxorubicin-treated cultures showed an increase of resistance only to doxorubicin. These data are in line with the literature (Kibria et al., 2014) . The development of increased resistance to doxorubicin can be explained by the selection of the population adapted to a particular stress and by genetic and/or epigenetic changes enabling effective survival. Since sensitivity to the other tested compounds increased, it can be suggested that the post-treatment cultures were re-generated by a part of the cellular population exhibiting anti-doxorubicin specific mechanisms.
The IC 50 value is a traditionally used metric of cytotoxicity estimating concentration of a compound that inhibits the cell division rate by 50%, and it is not adjusted for growth rates of the culture. Unlike GR 50 values, all IC 50 values for our post-treatment cultures indicated an increase of resistance to all tested cytotoxic compounds. While IC 50 values are traditionally used for assessment of cytotoxicity, they are difficult to reproduce (Hafner et al., 2017) and depend on the culture division times (PDTs). PDTs differ for various cell types and can be influenced by stress factors and cellular responses. In our post-treatment cultures PDTs were higher than in the control cultures; therefore the obtained IC 50 values reflect mainly a reduction of culture growth rates, not the development of multi-resistance. Since the R programme package GRmetrics does not estimate the statistical significance for IC 50 and GR 50 values, additional calculations for assessing sensitivity changes could be beneficial. However, the authors of GR 50 method have demonstrated the incompleteness of IC 50 values in data from a large-scale cell line and a chemotherapy compound data base (Genentech Cell Line Screening Initiative gCSI) and showed statistically significant (p < 0.001) correlation between sensitivity to the compound and PDTs (Hafner et al., 2016 (Hafner et al., , 2017 .
In our study sulforhodamine B (SRB) assay was used as a surrogate whole-well endpoint colorimetric assay to determine cell counts for population doubling time and cytotoxicity assessment. SRB binds to cellular proteins and the amount of bound dye is proportional to the number of cells if their size in the culture does not change. Morphology of cells, including their size, in post-treatment cultures differed not only from the controls, but was heterogeneous within the same culture. Therefore, we cannot exclude that the doxorubicin-induced alterations of cellular morphology and dimensions in post-treatment cultures interfered with the estimations and comparisons of PDTs and cytotoxicity due to the nature of SRB assay. Each tumour cell and/or subpopulation of cells responds to a particular cytotoxic compound differently (Leggett et al., 2016) , therefore a better method to determine sensitivity and cell counts for cytotoxicity assays would be a direct count of cells (and/or nuclei) by immunofluorescence microscopy or flow cytometry.
Changes of the stem-like properties in MDA-MB-231 cell cultures after doxorubicin treatment and in posttreatment culture. The properties of cancer stem-like cells (sSLC) in cultures exposed to doxorubicin were measured by long-term clonogenity assay and assessment of transcriptomic expression of several stemness-marker genes. There are no known unique and specific breast cSLC markers up to this day, and many studies use potential markers, such as CD44, CD24, ALDH1A1 (Al-Hajj et al., 2003 (Sheridan et al., 2006; Deng et al., 2017) . It has been shown (Deng et al., 2017) that in comparison to other triple negative breast cancer cell lines, MDA-MB-231 consists mostly of CD44 + /CD24 -cells with a relatively high resistance to doxorubicin and other anthracyclines. Our doxorubicin treated cultures displayed elevated transcriptional expression levels of both CD44 and especially of CD24 during the acute post-treatment period (DOX cultures), and returned to control levels during the recovery phase (DOX+1). The effects of various treatment modalities can depend on CD44/CD24 status of the cells, e.g., radiation-induced apoptosis was less pronounced in the pancreatic ductal adenocarcinoma-derived cell line fraction that consisted of CD44 + /CD24 + cells . Our study indicates that doxorubicin has a short-term effect on the transcriptional expression of CD44, CD24 and ALDH1A1.
ITGA6 and ITGB1 are genes of the integrin family, and elevated expression of both genes has been associated with the cSLC phenotype, tissue invasion and capability for metastasis (Brooks et al., 2016; Kim and Ryu, 2017) . Vassilopoulos et al. (2013) showed in vivo the tumour initiation properties of ITGA6+/ITGB1+/CD24+ cell populations. In our cultures, transcriptional expression of both genes decreased after the treatment with doxorubicin. This can be explained by increasing numbers of suspension cells after treatment, since both integrins are adhesion molecules. Post-treatment cultures displayed return of the expression levels of integrins to pre-treatment levels equivalent to the control cultures.
Changes in transcriptional expression of ALDH1A1 were observed in treated cultures. ALDH1A is another marker widely associated with the CSC phenotype; it has been associated with chemoresistance and has been shown to correlate with the outcome of treatment (El-Badawy et al., 2017) . In our control and post-treatment (DOX+1) MDA-MB-231 cultures the expression of ALDH1A1 was reduced, whereas a high expression was detected in the treated cultures (DOX). Elevated ALDH1A1 levels along with embryonic stem cell markers, have been observed in paclitaxel resistant MDA-MB-231 cells previously (Liu et al., 2013) . However, in our doxorubicin treated cultures, no elevated expression levels of the embryonic stem cell markers NANOG and POU5F1 (Oct3/4) were observed.
Embryonic stem cell markers are expressed in breast cancer cell lines (Ling et al., 2012) . Expression of both POU5F1 (Oct3/4) and NANOG has been associated with chemoresistance in a breast cancer stem cell fraction isolated by enrichment of MDA-MB-231 (Huang et al., 2015) . In our study, the transcriptional expression levels of POU5F1 (Oct3/4) slightly decreased in treated cultures, but returned to control levels in post-treatment cultures, suggesting that doxorubicin has no significant effect on the expression of embryonic stem cell markers, and perhaps putative cancer stem-like cell population enrichment could be one procedure to obtain an intrinsically chemoresistant fraction of breast cancer cell lines.
The characteristic ability of CSCs to regenerate the population was observed in post-treatment (DOX+1) culture -the recovery was provided by a relatively small number of cells (Weihua et al., 2011) . During post-treatment (DOX+1) cultures we observed non-adherent cell clusters resembling CSCs that have been described in several mammosphere studies (Jia et al., 2016; El-Badawy et al., 2017) . Long-term colony formation assay showed a significantly increased capability of post-treatment (DOX+1) cultures to form colonies in comparison to control cells, and this observation is in line with other studies of giant cells with CSC features (Weihua et al., 2011) .
Overall, transcriptional expression of several genes associated with CSCs along with the results of long-term colony formation assay suggest that treatment with doxorubicin selected the fraction of MDA-MB-231 cells exhibiting some stem-like features and increased ability to regenerate the cellular population. In the future, perhaps, a CSC enriched population could be better model to study multidrug resistance mechanisms in vitro.
CONCLUSIONS
In summary, a subpopulation of the doxorubicin resistant cells along with doxorubicin sensitive cells survived pulsed treatment with doxorubicin in the breast cancer cell line MDA-MB-231. Although the transcriptional expression levels of some stemness-associated marker genes increased, it was difficult to show that the proportion of cancer stem-like cells in cell culture has increased after the doxorubicin treatment. The heterogeneous culture after the doxorubicin treatment included giant cells along with suspension cells that had higher capacity to regenerate the population, indicating a correlation between the development of resistance and the selection of more aggressive and viable cancer cells.
